Introgen Preclinical Studies Indicate Therapeutic Potential of INGN 241 In Lung Cancer
(PR Newswire)...``The ability of the mda-7 gene to suppress the growth of lung tumors in a preclinical setting had not been shown before,......``These studies have demonstrated that INGN 241 may have both anti-tumor and anti-angiogenic activities.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain and breast cancer....- Mar 29 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010329/dath015.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines